MorphoSys AG (Frankfurt Stock Exchange: MOR; Prime Standard Segment; TecDAX) has successfully placed 384,338 shares to international institutional investors, at a price of EUR 44.50 per share. The issue was several times over-subscribed. The Company raised gross proceeds of approx. EUR 17.1 million raising the company's cash balance to approx. EUR 60 million. WestLB AG acted as Lead Manager of the transaction joined by DZ BANK AG as Co-Lead Manager.
With the capital increase, the number of issued shares will increase from 6,234,423 to 6,639,618 shares, corresponding to an increase of subscribed share capital in common stock from EUR 18,703,269 to EUR 19,918,845.
'Today's successful funding allows us the flexibility to further expand the research antibody side of our business. The unit has witnessed significant organic growth, not to mention two acquisitions since 2005,' commented Dave Lemus, Chief Financial Officer at MorphoSys AG.
With the capital increase, the number of issued shares will increase from 6,234,423 to 6,639,618 shares, corresponding to an increase of subscribed share capital in common stock from EUR 18,703,269 to EUR 19,918,845.
'Today's successful funding allows us the flexibility to further expand the research antibody side of our business. The unit has witnessed significant organic growth, not to mention two acquisitions since 2005,' commented Dave Lemus, Chief Financial Officer at MorphoSys AG.